Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Events

10 May 2016 - 16 May 2016
11 May 2016 - 13 May 2016

Experimental Drug Prevents Ischemia in Mouse Muscular Dystrophy Model

By BiotechDaily International staff writers
Posted on 22 Nov 2012
Print article
Treating mice with a form of muscular dystrophy that closely mimics human Duchenne muscular dystrophy (DMD) with the experimental drug HCT 1026 restored normal blood flow to muscles stressed by a hormone-induced exercise regimen.

The dystrophin deficiency that characterizes DMD causes loss of the neuronal enzyme nitric oxide synthase from the sarcolemma, producing functional ischemia when the muscles are exercised. Investigators at Cedars-Sinai Heart Institute (Los Angeles, CA, USA) asked whether functional muscle ischemia could be eliminated and normal blood flow regulation restored by treatment with an exogenous nitric oxide (NO)-donating drug.

The drug under evaluation was HCT 1026, a NO-donating nonsteroidal anti-inflammatory agent that had previously been shown to slow progression of DMD in the mdx mouse muscular dystrophy model.

In the current study, beginning at eight weeks of age, mdx mice were fed a standard diet supplemented with 1% soybean oil alone or in combination with a low or high dose of HCT 1026. After one month of treatment, vasoconstrictor responses to intra-arterial norepinephrine (NE) were compared in resting and contracting hindlimbs.

Results published in the November 5, 2012, online edition of the journal PLOS ONE revealed that in untreated mdx mice, the usual effect of muscle contraction to attenuate NE-mediated vasoconstriction was impaired, resulting in functional ischemia. This NE-induced functional ischemia was unaffected by low dose HCT 1026 but was alleviated by the high dose of the drug. The beneficial effect of high dose HCT 1026 was maintained with treatment up to three months.

"There is an urgent unmet need for effective therapeutic options for this devastating disease," said senior author Dr. Ronald G. Victor, professor of cardiology at Cedars-Sinai Heart Institute. "If we can improve blood flow in muscular dystrophy patients, we may be able to preserve some muscle function over a longer period of time."

The authors stressed that they did not expect these novel nitric oxide-donating compounds to cure DMD, but did hope that the improved blood flow that they induced could reduce muscle fatigue and injury, allowing patients to be more active while slowing down the loss of vital muscle tissue.

Related Links:
Cedars-Sinai Heart Institute




Print article

Channels

Genomics/Proteomics

view channel
Image: An artistic rendering of the Zika virus structure (Photo courtesy of Dr. Guntur Fibriansah, Duke-NUS Medical School).

High Resolution Structure of Zika virus Expected to Aid Vaccine Development

A team of molecular virologists used advanced cryo-electron microscopy techniques to establish a high-resolution structure for the Zika virus, a formerly neglected pathogen that has recently been associated... Read more

Drug Discovery

view channel

Experimental Small-Molecule Anticancer Drug Blocks RAS-binding Domains

The experimental small-molecule anticancer drug rigosertib was shown to block tumor growth by acting as an RAS-mimetic and interacting with the RAS binding domains of RAF kinases, resulting in their inability to bind to RAS, which inhibited the RAS-RAF-MEK pathway. Oncogenic activation of RAS genes due to point mutations... Read more

Biochemistry

view channel
Image: A space-filling model of the anticonvulsant drug carbamazepine (Photo courtesy of Wikimedia Commons).

Wastewater May Contaminate Crops with Potentially Dangerous Pharmaceuticals

Reclaimed wastewater used to irrigate crops is contaminated with pharmaceutical residues that can be detected in the urine of those who consumed such produce. Investigators at the Hebrew University... Read more

Lab Technologies

view channel

Huge Modifiable Biomedical Database to Be Available on the Wikidata Site

Genome researchers are exploiting the power of the open Internet community Wikipedia database to create a comprehensive resource for geneticists, molecular biologists, and other interested life scientists. While efficiency in generating scientific data improves almost daily, applying meaningful relationships between... Read more

Business

view channel

European Biotech Agreement to Promote Antigen-Drug Conjugation Technology

Two European biotech companies have joined forces to exploit and commercialize an innovative, site-specific ADC (antigen-drug conjugate) conjugation technology. ProBioGen (Berlin, Germany), a company specializing in the development and manufacture of complex glycoproteins and Eucodis Bioscience (Vienna, Austria), a... Read more
Copyright © 2000-2016 Globetech Media. All rights reserved.